These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34766230)

  • 21. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
    Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.
    Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M
    Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substance P enhances the local activation of NK
    Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
    BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
    Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
    Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
    Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
    Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma.
    Yang Y; Cao X; Wang Y; Wu X; Zhou P; Miao L; Deng X
    Liver Int; 2024 Jul; 44(7):1651-1667. PubMed ID: 38554043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways.
    Javid H; Asadi J; Zahedi Avval F; Afshari AR; Hashemy SI
    Mol Biol Rep; 2020 Mar; 47(3):2253-2263. PubMed ID: 32072401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
    Matalińska J; Świć A; Lipiński P; Misicka A
    Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
    Rezaei S; Assaran Darban R; Javid H; Hashemy SI
    Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression.
    Li M; Ma H; Zhang S; Peng Y; Ding L; Zhang Y; Min P
    Front Endocrinol (Lausanne); 2022; 13():1077514. PubMed ID: 36686487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The neuropeptide substance P regulates aldosterone secretion in human adrenals.
    Wils J; Duparc C; Cailleux AF; Lopez AG; Guiheneuf C; Boutelet I; Boyer HG; Dubessy C; Cherifi S; Cauliez B; Gobet F; Defortescu G; Ménard JF; Louiset E; Lefebvre H
    Nat Commun; 2020 May; 11(1):2673. PubMed ID: 32471973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.
    Zhang XW; Li L; Hu WQ; Hu MN; Tao Y; Hu H; Miao XK; Yang WL; Zhu Q; Mou LY
    Cell Death Dis; 2022 Jan; 13(1):41. PubMed ID: 35013118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
    Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
    Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
    Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
    Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).
    Chernova I; Lai JP; Li H; Schwartz L; Tuluc F; Korchak HM; Douglas SD; Kilpatrick LE
    J Leukoc Biol; 2009 Jan; 85(1):154-64. PubMed ID: 18835883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs.
    Ebrahimi S; Javid H; Alaei A; Hashemy SI
    Clin Genet; 2020 Oct; 98(4):322-330. PubMed ID: 32266968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.